Aytu BioPharma, Inc.

NasdaqCM:AYTU 株式レポート

時価総額：US$10.0m

Aytu BioPharma マネジメント

マネジメント 基準チェック /24

Aytu BioPharmaの CEO はJosh Disbrowで、 Apr2015年に任命され、 の在任期間は 9.58年です。 の年間総報酬は$ 928.22Kで、 63.6%給与と36.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.17%を直接所有しており、その価値は$ 116.89K 。経営陣と取締役会の平均在任期間はそれぞれ2.4年と8.3年です。

主要情報

Josh Disbrow

最高経営責任者

US$928.2k

報酬総額

CEO給与比率63.6%
CEO在任期間9.6yrs
CEOの所有権1.2%
経営陣の平均在職期間2.4yrs
取締役会の平均在任期間8.3yrs

経営陣の近況

It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Jun 20
It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Recent updates

Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32%

Nov 15
Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32%

Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly?

Nov 01
Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly?

It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Jun 20
It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden

Jun 14
Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden

US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Feb 17
US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Feb 16
Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

Jan 23
Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too

Sep 29
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too

Aytu stock falls amid suspending clinical programs to save costs

Oct 13

Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M

Sep 27

Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder

Sep 14

Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders

Aug 16

Aytu BioPharma plunges on pricing $10M stock and warrants offering

Aug 09

Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00

May 19
Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00

Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?

Sep 11
Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?

Aytu BioPharma up 21% in afternoon trading

Jun 21

Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now

May 15
Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now

CEO報酬分析

Aytu BioPharma の収益と比較して、Josh Disbrow の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$7m

Jun 30 2024US$928kUS$590k

-US$16m

Mar 31 2024n/an/a

-US$13m

Dec 31 2023n/an/a

-US$17m

Sep 30 2023n/an/a

-US$24m

Jun 30 2023US$708kUS$590k

-US$17m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022n/an/a

-US$77m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022US$590kUS$590k

-US$109m

Mar 31 2022n/an/a

-US$112m

Dec 31 2021n/an/a

-US$84m

Sep 30 2021n/an/a

-US$82m

Jun 30 2021US$6mUS$545k

-US$58m

Mar 31 2021n/an/a

-US$42m

Dec 31 2020n/an/a

-US$22m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020US$2mUS$608k

-US$14m

Mar 31 2020n/an/a

-US$25m

Dec 31 2019n/an/a

-US$24m

Sep 30 2019n/an/a

-US$29m

Jun 30 2019US$1mUS$330k

-US$27m

Mar 31 2019n/an/a

-US$12m

Dec 31 2018n/an/a

-US$10m

Sep 30 2018n/an/a

-US$9m

Jun 30 2018US$606kUS$303k

-US$10m

報酬と市場: Joshの 総報酬 ($USD 928.22K ) は、 US市場 ($USD 647.72K ) の同規模の企業の平均を上回っています。

報酬と収益: Joshの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Josh Disbrow (49 yo)

9.6yrs

在職期間

US$928,217

報酬

Mr. Joshua R. Disbrow, also known as Josh, serves as Chief Executive Officer at Aytu Biopharma, Inc. since April 16, 2015 and served as its Chairman until 2024. He served as President at Aytu Biopharma, In...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Joshua Disbrow
CEO & Director9.6yrsUS$928.22k1.17%
$ 116.9k
Jarrett Disbrow
Chief Business Officer2yrsUS$542.10k0.21%
$ 20.9k
Greg Pyszczymuka
Chief Commercial Officer2.8yrsUS$516.30k0.38%
$ 37.8k
Ryan Selhorn
CFO, Corporate Secretary & Treasurerno dataデータなし0.26%
$ 25.9k
Margaret Cabano
Vice President of Operationsno dataデータなしデータなし

2.4yrs

平均在職期間

46.5yo

平均年齢

経験豊富な経営陣: AYTUの経営陣は 経験豊富 であると考えられます ( 2.4年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Joshua Disbrow
CEO & Director8.8yrsUS$928.22k1.17%
$ 116.9k
Vivian Liu
Independent Director2.3yrsUS$77.60k0.16%
$ 16.0k
John Donofrio
Independent Chairman8.3yrsUS$107.60k0.061%
$ 6.1k
Carl Dockery
Independent Director8.6yrsUS$72.60k0.17%
$ 17.0k
Abhinav Jain
Independent Director1.4yrsUS$79.30k0.15%
$ 15.5k

8.3yrs

平均在職期間

57yo

平均年齢

経験豊富なボード: AYTUの 取締役会 は 経験豊富 であると考えられます ( 8.3年の平均在任期間)。